Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Exploration of extending ketamine’s antidepressant effects by enhancing intracellular signaling pathways in major depressive ...

Researchers are shining light on new stages of the ERK pathway. Researchers at the ... While their previous work focused on aspects of the signaling pathway from the liver to the pancreas, this ...

Targeting ERK signaling through DUSP6 inhibition extended the antidepressant effects of a single ketamine dose in mice. Findings indicate that transiently increasing ERK activity may sustain ...

Creative Biolabs recently updated its antibody chip platform, expanding product arrays for phosphorylation signaling and ...

Researchers at the Max Planck Institute for Biology of Aging have discovered that the combination of the two cancer drugs, ...

Roughly 10 percent of the U.S. population is afflicted with major depressive disorder at any given time, and up to 20 percent will exhibit MDD symptoms over their lifetimes.

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...

A new review sheds light on the complex molecular mechanisms behind Angelman syndrome (AS), a rare neurogenetic disorder, and ...